^
    Back
    Association details:
    Biomarker:HER-2 overexpression
    Cancer:HER2 Positive Breast Cancer
    Drug:lapatinib (EGFR inhibitor, HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ASCO 2018
    Title:

    PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.

    Published date:
    05/16/2018
    Excerpt:
    EGF104900 randomized 296 women with HER2+ advanced BC who experienced progression on prior T-containing regimens to receive either L alone or L+T….Median PFS of the HER2-E/ERBB2H group was 3.5 months (2.6-54) compared to 1.2 months (1-1.7) in others. The ORR and CBR of the HER2-E/ERBB2H group were higher compared to others (ORR 16.25% vs. 3.66%; p = 0.017 and CBR 66.25% vs. 26.83%; P < 0.001).
    DOI:
    10.1200/JCO.2018.36.15_suppl.1025
    Trial ID:
    NCT00320385
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Hormone Receptor Positive Breast Cancer)
    New
    Excerpt:
    Tyverb is indicated for the treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2):...in combination with an aromatase inhibitor for post-menopausal women with hormone-receptor-positive metastatic disease, not currently intended for chemotherapy.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer

    Excerpt:
    ...- HER2 overexpressing breast cancer defined as 3+ staining by immunohistochemistry, or HER2 gene amplification by FISH...
    Trial ID:
    NCT00470847
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases

    Excerpt:
    ...- HER2 overexpressing breast cancer, defined as 3+ staining by immunohistochemistry (IHC), or 2+ staining by IHC in conjunction with HER2 gene amplification by fluorescent in situ hybridization (FISH), or HER2 gene amplification by FISH alone (in patients whose tumor blocks were...
    Trial ID:
    NCT00098605
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

    Excerpt:
    ...HER2-positive is defined as HER2 overexpression and/or amplification as determined by immunohistochemistry (3+) or fluorescence in situ hybridization (FISH) (>= 2.0)...
    Trial ID:
    NCT01705340
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer

    Excerpt:
    ...- HER2-overexpressing breast cancer (3+ staining by immunohistochemistry or HER2 gene amplification by fluorescent in situ hybridization [FISH] or silver in situ hybridization [SISH] >= 2.0)...
    Trial ID:
    RTOG 1119
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients

    Excerpt:
    ...HER2 overexpressing tumors defined as HercepTest score of 3+, or > 10% cells moderately or strongly HER2 positive by other methods, or semi-quantitative score of >5 (in Dr. ...
    Trial ID:
    NCT00455039
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Neoadjuvant GW572016 to Treat Breast Cancer

    Excerpt:
    ...HER2 overexpressing tumors defined as HercepTest score of 3+, or >/- 10% cells moderately or strongly HER2 positive by other methods, or semi-quantitative score of >/- 5 (in Dr. ...
    Trial ID:
    NCT00206427
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients

    Excerpt:
    ...- Metastatic, histologically confirmed breast cancer that over-expresses ErbB2 (3+ by IHC; FISH or CISH positive)....
    Trial ID:
    NCT00821054
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    The Myocet/Lapatinib Study. ICORG 10-03, V5

    Excerpt:
    ...Documented HER2 overexpression (IHC 3+ or FISH or CISH positive) 5....
    Trial ID:
    NCT01495884
    Less C2 evidence
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Heliyon
    Title:

    The Nrf2 inhibitor brusatol synergistically enhances the cytotoxic effect of lapatinib in HER2-positive cancers

    Published date:
    08/28/2022
    Excerpt:
    Brusatol in combination with lapatinib synergistically inhibited the growth of HER2-overexpressed SK-BR-3, SK-OV-3 and AU565 cells...In this study, we investigated the anti-tumor efficacy of Nrf2 inhibitor, brusatol in combination with dual HER2/EGFR inhibitor, lapatinib...
    Secondary therapy:
    brusatol
    DOI:
    10.1016/j.heliyon.2022.e10410